Dane Leone
Stock Analyst at Raymond James
(1.18)
# 3,637
Out of 4,918 analysts
68
Total ratings
36.36%
Success rate
-9.3%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.65 | +515.38% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $8.19 | +449.45% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $36.63 | -18.10% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $558.87 | +69.99% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.12 | +513.21% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $47.37 | -2.89% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $32.69 | +111.07% | 5 | May 8, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $3.36 | +763.10% | 2 | Apr 19, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $2.96 | +170.73% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $11.92 | +17.45% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $7.96 | +628.64% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $12.80 | +446.88% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.08 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $36.69 | +71.71% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $44.23 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.63 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $40.81 | +59.27% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $296.88 | -14.11% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $2.96 | +981.08% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $167.33 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.65
Upside: +515.38%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $8.19
Upside: +449.45%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $36.63
Upside: -18.10%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $558.87
Upside: +69.99%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.12
Upside: +513.21%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $47.37
Upside: -2.89%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $32.69
Upside: +111.07%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $3.36
Upside: +763.10%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $2.96
Upside: +170.73%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $11.92
Upside: +17.45%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $7.96
Upside: +628.64%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $12.80
Upside: +446.88%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.08
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $36.69
Upside: +71.71%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $44.23
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.63
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $40.81
Upside: +59.27%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $296.88
Upside: -14.11%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $2.96
Upside: +981.08%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $167.33
Upside: -